Il trattamento della salute mentale e fisica dovrebbe essere fornito insieme ai bambini e ai giovani con epilessia. La formazione degli operatori sanitari (HCP) nei servizi per l’epilessia per fornire interventi di salute mentale è un modo importante per facilitare l’assistenza integrata. Tredici operatori sanitari sono stati formati sulla fornitura dell’intervento. Un pneumologo pediatrico ha determinato la gravità e il controllo dell’asma di ogni partecipante durante una visita clinica. Per ogni paziente sono stati generati un punteggio CASI e ACT / C-ACT.
determinare la fattibilità della valutazione e del trattamento psicologico forniti a distanza per le difficoltà di salute mentale forniti dagli operatori sanitari nelle cliniche pediatriche per l’epilessia con una formazione formale limitata in interventi psicologici. Abbiamo ipotizzato che sarebbe stato (i) possibile formare gli operatori sanitari per fornire l’intervento psicologico e (ii) che i partecipanti che ricevevano la terapia psicologica avrebbero riportato riduzioni dei sintomi di difficoltà di salute mentale tra cui ansia, depressione e difficoltà comportamentali e migliorato la qualità della vita .
Trentaquattro bambini e giovani con epilessia che presentavano sintomi alteranti di una difficoltà di salute mentale comune (ansia, depressione, comportamento dirompente e / o trauma) sono stati assegnati a ricevere 6 mesi di un intervento cognitivo comportamentale modulare fornito da un operatore sanitario con limitata esperienza di terapia psicologica formale.La competenza degli operatori sanitari è stata valutata in un processo a due fasi. Le misurazioni riferite dai genitori dei sintomi di salute mentale e della qualità della vita sono state completate al basale e dopo l’intervento. Sono stati utilizzati test t accoppiati per analizzare i cambiamenti nei sintomi nel tempo.
tutti i tredici operatori sanitari che hanno partecipato alla formazione sono stati considerati competenti nell’erogazione terapeutica entro la fine del periodo di formazione. Ventitré pazienti hanno completato le misure pre e post intervento e sono stati inclusi nell’analisi. Ci sono stati miglioramenti statisticamente significativi in: sintomi di problemi di salute mentale (p = 0,01; d di Cohen = 0,62), impatto totale dei problemi di salute mentale (p = 0,03; d di Cohen = 0,52), sintomi di ansia e depressione (p = 0,02; d = 0,57) e qualità della vita (p = 0,01; d di Cohen = 0,57).
un trattamento cognitivo comportamentale modulare fornito per telefono da operatori sanitari con esperienza limitata di terapia psicologica era fattibile ed efficace nel trattamento dei problemi di salute mentale nei bambini e nei giovani con epilessia. Anche la qualità della vita correlata alla salute è migliorata durante la durata del trattamento. È necessario uno studio randomizzato controllato (RCT) per dimostrare l’efficacia dell’intervento.
Migliori pratiche di prescrizione di antibiotici per infezioni respiratorie attraverso l’uso di set di ordini computerizzati e sessioni educative nelle cliniche pediatriche
I sistemi computerizzati di supporto alle decisioni cliniche (CDSS) hanno mostrato un’efficacia promettente nel migliorare la prescrizione ambulatoriale di antibiotici. Abbiamo sviluppato un intervento sotto forma di set di ordini EPIC (Verona, WI, USA) comprendenti percorsi di trattamento ambulatoriale per 3 infezioni respiratorie acute batteriche pediatriche (ARI) accoppiati a sessioni educative. Quattro cliniche pediatriche sono state randomizzate in bracci di intervento e di controllo durante periodi di studio pre e postimplementazione.
Nelle cliniche di intervento, l’istruzione è stata fornita tra i 2 periodi di studio e le serie di ordini EPIC sono diventate disponibili all’inizio del periodo postimplementazione. L’endpoint primario era la percentuale di prescrizione di antibiotici di prima linea e gli endpoint secondari includevano la durata dell’antibiotico e la modifica della prescrizione di antibiotici entro 14 giorni.
sono state incluse un totale di 2690 prescrizioni di antibiotici.
Durante la fase di pre-implementazione, non vi era alcuna differenza nella prescrizione di antibiotici di prima linea o nella durata dell’antibiotico tra i studiare le armi. Dopo l’implementazione, le cliniche di intervento avevano una percentuale più alta di prescrizione di antibiotici di prima linea e una durata dell’antibiotico più breve ispetto a le cliniche di controllo. La percentuale di antibiotici modificati era piccola in tutte le cliniche (1,1% -1,6%) e non differiva prima e dopo l’intervento.
un CDSS computerizzato che coinvolge percorsi di trattamento sotto forma di set di ordini accoppiati a sessioni educative è stato associato a una percentuale più alta di prescrizione di antibiotici di prima linea e una durata più breve dell’antibiotico per il trattamento ambulatoriale delle ARI batteriche pediatriche. Metodi I bambini di età compresa tra 5 e 18 anni con una diagnosi medica di asma persistente sono stati reclutati da un centro di assistenza terziaria.
La proporzione di casi di malattie infettive, i suoi fattori associati e l’appropriatezza della prescrizione di antimicrobici tra i pazienti pediatrici rifugiati Rohingya nelle cliniche mobili IMARET
I Rohingya sono fuggiti dalla loro casa per sfuggire alla persecuzione etnica. A causa del loro status di rifugiati, hanno difficoltà ad accedere all’assistenza sanitaria che porta a mortalità e morbilità evitabili. Si dice che le malattie infettive siano tra le cause. Per facilitare l’accesso all’assistenza sanitaria, IMAM Response and Relief Team (IMARET) fornisce loro una clinica mensile gratuita. L’obiettivo di questo studio è determinare la proporzione di malattie infettive e l’adeguatezza dell’uso di antimicrobici tra i suoi pazienti pediatrici. È stato condotto nel 2017, tramite campionamento universale.
Le informazioni recuperate sono state ottenute tramite interviste e cartelle cliniche. La maggior parte delle diagnosi erano malattie infettive (57,1%), che includono infezioni respiratorie (77,3%), pelle (13,6%), infezioni gastrointestinali (4,5%), occhi e orecchie (entrambe 1%). L’albendazolo (40,7%) era il più prescritto. Solo al 7,4% sono stati prescritti antimicrobici in modo appropriato. L’età (p = 0,005) e il BMI (p = 0,006) erano significativamente associati alle infezioni.
Single Donor Human Pediatric Plasma |
IPLASPED11141 |
Innovative research |
each |
EUR 253 |
|
Description: Single Donor Human Pediatric Plasma |
Single Donor Human Pediatric Plasma |
IPLASPED11145 |
Innovative research |
each |
EUR 1176 |
|
Description: Single Donor Human Pediatric Plasma |
Single Donor Human Pediatric Plasma |
IPLASPED15171 |
Innovative research |
each |
EUR 253 |
|
Description: Single Donor Human Pediatric Plasma |
Single Donor Human Pediatric Plasma |
IPLASPED15175 |
Innovative research |
each |
EUR 1176 |
|
Description: Single Donor Human Pediatric Plasma |
Single Donor Human Pediatric Plasma |
IPLASPED461 |
Innovative research |
each |
EUR 253 |
|
Description: Single Donor Human Pediatric Plasma |
Single Donor Human Pediatric Plasma |
IPLASPED465 |
Innovative research |
each |
EUR 1176 |
|
Description: Single Donor Human Pediatric Plasma |
Single Donor Human Pediatric Plasma |
IPLASPED7101 |
Innovative research |
each |
EUR 253 |
|
Description: Single Donor Human Pediatric Plasma |
Single Donor Human Pediatric Plasma |
IPLASPED7105 |
Innovative research |
each |
EUR 1176 |
|
Description: Single Donor Human Pediatric Plasma |
Single Donor Human Pediatric SARS-Cov-2 Positive Plasma |
IPLASPEDCOV2P100UL |
Innovative research |
each |
EUR 127 |
|
Description: Single Donor Human Pediatric SARS-Cov-2 Positive Plasma |
RealScreen Pediatric FSH ELISA Kit |
EL103-096 |
GenDepot |
96T |
EUR 2198.4 |
Single Donor Human Pediatric Serum |
ISERSPED031 |
Innovative research |
each |
EUR 269 |
|
Description: Single Donor Human Pediatric Serum |
Single Donor Human Pediatric Serum |
ISERSPED035 |
Innovative research |
each |
EUR 1268 |
|
Description: Single Donor Human Pediatric Serum |
Single Donor Human Pediatric Serum |
ISERSPED11141 |
Innovative research |
each |
EUR 269 |
|
Description: Single Donor Human Pediatric Serum |
Single Donor Human Pediatric Serum |
ISERSPED11145 |
Innovative research |
each |
EUR 1268 |
|
Description: Single Donor Human Pediatric Serum |
Single Donor Human Pediatric Serum |
ISERSPED15171 |
Innovative research |
each |
EUR 269 |
|
Description: Single Donor Human Pediatric Serum |
Single Donor Human Pediatric Serum |
ISERSPED15175 |
Innovative research |
each |
EUR 1268 |
|
Description: Single Donor Human Pediatric Serum |
Single Donor Human Pediatric Serum |
ISERSPED460 |
Innovative research |
each |
EUR 269 |
|
Description: Single Donor Human Pediatric Serum |
Single Donor Human Pediatric Serum |
ISERSPED465 |
Innovative research |
each |
EUR 1268 |
|
Description: Single Donor Human Pediatric Serum |
Single Donor Human Pediatric Serum |
ISERSPED7101 |
Innovative research |
each |
EUR 269 |
|
Description: Single Donor Human Pediatric Serum |
Single Donor Human Pediatric Serum |
ISERSPED7105 |
Innovative research |
each |
EUR 1268 |
|
Description: Single Donor Human Pediatric Serum |
Single Donor Pediatric Human Urine |
IRHUSUREPED10131 |
Innovative research |
each |
EUR 322 |
|
Description: Single Donor Pediatric Human Urine |
Single Donor Pediatric Human Urine |
IRHUSUREPED10135 |
Innovative research |
each |
EUR 1526 |
|
Description: Single Donor Pediatric Human Urine |
Single Donor Pediatric Human Urine |
IRHUSUREPED141 |
Innovative research |
each |
EUR 322 |
|
Description: Single Donor Pediatric Human Urine |
Single Donor Pediatric Human Urine |
IRHUSUREPED14171 |
Innovative research |
each |
EUR 322 |
|
Description: Single Donor Pediatric Human Urine |
Single Donor Pediatric Human Urine |
IRHUSUREPED14175 |
Innovative research |
each |
EUR 1526 |
|
Description: Single Donor Pediatric Human Urine |
Single Donor Pediatric Human Urine |
IRHUSUREPED145 |
Innovative research |
each |
EUR 1526 |
|
Description: Single Donor Pediatric Human Urine |
Single Donor Pediatric Human Urine |
IRHUSUREPED591 |
Innovative research |
each |
EUR 322 |
|
Description: Single Donor Pediatric Human Urine |
Single Donor Pediatric Human Urine |
IRHUSUREPED595 |
Innovative research |
each |
EUR 1526 |
|
Description: Single Donor Pediatric Human Urine |
Single Donor Human Pediatric Saliva |
IRHUSSLPED10171 |
Innovative research |
each |
EUR 181 |
|
Description: Single Donor Human Pediatric Saliva |
Single Donor Human Pediatric Saliva |
IRHUSSLPED10175 |
Innovative research |
each |
EUR 866 |
|
Description: Single Donor Human Pediatric Saliva |
Single Donor Human Pediatric Saliva |
IRHUSSLPED391 |
Innovative research |
each |
EUR 181 |
|
Description: Single Donor Human Pediatric Saliva |
Single Donor Human Pediatric Saliva |
IRHUSSLPED395 |
Innovative research |
each |
EUR 866 |
|
Description: Single Donor Human Pediatric Saliva |
Single Donor Human Pediatric Whole Blood |
IWB1SPED031 |
Innovative research |
each |
EUR 322 |
|
Description: Single Donor Human Pediatric Whole Blood |
Single Donor Human Pediatric Whole Blood |
IWB1SPED035 |
Innovative research |
each |
EUR 1453 |
|
Description: Single Donor Human Pediatric Whole Blood |
Single Donor Human Pediatric Whole Blood |
IWB1SPED11141 |
Innovative research |
each |
EUR 322 |
|
Description: Single Donor Human Pediatric Whole Blood |
Single Donor Human Pediatric Whole Blood |
IWB1SPED11145 |
Innovative research |
each |
EUR 1453 |
|
Description: Single Donor Human Pediatric Whole Blood |
Single Donor Human Pediatric Whole Blood |
IWB1SPED15171 |
Innovative research |
each |
EUR 322 |
|
Description: Single Donor Human Pediatric Whole Blood |
Single Donor Human Pediatric Whole Blood |
IWB1SPED15175 |
Innovative research |
each |
EUR 1453 |
|
Description: Single Donor Human Pediatric Whole Blood |
Single Donor Human Pediatric Whole Blood |
IWB1SPED461 |
Innovative research |
each |
EUR 322 |
|
Description: Single Donor Human Pediatric Whole Blood |
Single Donor Human Pediatric Whole Blood |
IWB1SPED465 |
Innovative research |
each |
EUR 1453 |
|
Description: Single Donor Human Pediatric Whole Blood |
Single Donor Human Pediatric Whole Blood |
IWB1SPED7101 |
Innovative research |
each |
EUR 322 |
|
Description: Single Donor Human Pediatric Whole Blood |
Single Donor Human Pediatric Whole Blood |
IWB1SPED7105 |
Innovative research |
each |
EUR 1453 |
|
Description: Single Donor Human Pediatric Whole Blood |
Single Donor Human Pediatric Fecal Matter |
IRHUSFMPED03 |
Innovative research |
each |
EUR 536 |
|
Description: Single Donor Human Pediatric Fecal Matter |
Single Donor Human Pediatric Fecal Matter |
IRHUSFMPED1114 |
Innovative research |
each |
EUR 536 |
|
Description: Single Donor Human Pediatric Fecal Matter |
Single Donor Human Pediatric Fecal Matter |
IRHUSFMPED1517 |
Innovative research |
each |
EUR 536 |
|
Description: Single Donor Human Pediatric Fecal Matter |
Single Donor Human Pediatric Fecal Matter |
IRHUSFMPED46 |
Innovative research |
each |
EUR 536 |
|
Description: Single Donor Human Pediatric Fecal Matter |
Single Donor Human Pediatric Fecal Matter |
IRHUSFMPED710 |
Innovative research |
each |
EUR 536 |
|
Description: Single Donor Human Pediatric Fecal Matter |
Human Pediatric Peripheral Blood Mononuclear Cells |
ABC-TC4351 |
AcceGen |
1 vial |
Ask for price |
|
Description: Included Diagnoses: Normal, Asthma, Crohn's Disease, IBD, Ulcerative Colitis, Type I Diabetes. |
Single Donor Human Pediatric SARS-Cov-2 Positive Serum |
ISERSPEDCOV2P100UL |
Innovative research |
each |
EUR 127 |
|
Description: Single Donor Human Pediatric SARS-Cov-2 Positive Serum |
Pediatric malignant tumor tissue array with normal tissue as control |
PC701 |
TissueArray |
each |
EUR 306 |
Description: Pediatric malignant tumor tissue array with normal tissue as control, 70 cases/ 70 cores |
Stomach cancer with matched adjacent normal tissue array (age<35 years old) |
ST8018 |
TissueArray |
each |
EUR 306 |
Description: Stomach cancer with matched adjacent normal tissue array (age<35 years old), including WHO grade, Borrmann grade and Lauren type, 40 cases/80 cores |
Plasma Sample Diluent (Antigen-Down SD) |
694 |
Immunochemistry |
100 mL |
EUR 57.25 |
Plasma Sample Diluent (Antigen-Down SD) |
695 |
Immunochemistry |
500 mL |
EUR 227.5 |
Plasma Sample Diluent (Antigen-Down)-SD2 |
KF17353 |
Neuromics |
500 ml |
EUR 338.4 |
Recent Years Collection Samples. Multiple ovarian tumor tissue array |
OV401sur |
TissueArray |
each |
EUR 416 |
Description: Recent Years Collection Samples. Multiple ovarian tumor tissue array, including survival data, pathology grade, TNM and clinical stage (AJCC 8.0), 20 cases/40 cores (1.5mm) |
ANTIGEN DOWN PLASMA SAMPLE DILUENT Reagent |
GWB-Q00209 |
GenWay Biotech |
100 ml |
Ask for price |
ANTIGEN DOWN PLASMA SAMPLE DILUENT Reagent |
GWB-Q00210 |
GenWay Biotech |
1000 ml |
Ask for price |
Sample, Antibody and Conjugate Diluent (20X) for ELISA (For serum, plasma sample conservation and low background) |
80066 |
Alpha Diagnostics |
50 ml |
EUR 278.4 |
OOSA09671-1L - ANTIGEN DOWN PLASMA SAMPLE DILUENT Accessory Reagent |
OOSA09671-1L |
Aviva Systems Biology |
1000ml |
EUR 669 |
|
OOSA11219-100ML - ANTIGEN DOWN PLASMA SAMPLE DILUENT Accessory Reagent |
OOSA11219-100ML |
Aviva Systems Biology |
100ml |
EUR 169 |
|
NS/0 Sample Diluent |
F223A |
Cygnus Technologies |
1000 ml |
EUR 1002 |
|
Description: NS/0 Sample Diluent by Cygnus Technologies is available in Europe via Gentaur. |
NS/0 Sample Diluent |
F223A-100 |
Cygnus Technologies |
100 ml |
EUR 308.4 |
|
Description: NS/0 Sample Diluent by Cygnus Technologies is available in Europe via Gentaur. |
NS/0 Sample Diluent |
F223A-500 |
Cygnus Technologies |
500 ml |
EUR 585.6 |
|
Description: NS/0 Sample Diluent by Cygnus Technologies is available in Europe via Gentaur. |
Non-small cell lung cancer NSCLC tissue array (all samples are from recent 4 years) with multiple IHC markers (PD-L1 |
LC1461 |
TissueArray |
each |
EUR 552 |
Description: Non-small cell lung cancer NSCLC tissue array (all samples are from recent 4 years) with multiple IHC markers (PD-L1, ALK, ROS1+, CD70, HLA1, MPO, CD3 and CD8, containing stained intensity, location and cell type), including pathology grade, TNM and clinical stage, 73 cases/146 cores |
SP2/0 Sample Diluent |
F183A |
Cygnus Technologies |
1000 ml |
EUR 1002 |
|
Description: SP2/0 Sample Diluent by Cygnus Technologies is available in Europe via Gentaur. |
SP2/0 Sample Diluent |
F183A-100 |
Cygnus Technologies |
100 ml |
EUR 308.4 |
|
Description: SP2/0 Sample Diluent by Cygnus Technologies is available in Europe via Gentaur. |
SP2/0 Sample Diluent |
F183A-500 |
Cygnus Technologies |
500 ml |
EUR 585.6 |
|
Description: SP2/0 Sample Diluent by Cygnus Technologies is available in Europe via Gentaur. |
Low Sample Volume Mouse Plasma Protease C1 Inhibitor / C1INH (SERPING1) ELISA Kit |
abx352615-96tests |
Abbexa |
96 tests |
EUR 750 |
Exosome isolation Solution - Serum/ Plasma (easy version of P101, 95% pure exosome) sample |
P101EZ--sample |
101Bio |
- |
Ask for price |
2019-nCoV IgG/IgM RapiCard InstaTest for Whole Blood/Serum/Plasma samples |
GEN-176552-25tests |
Cusabio |
25 tests |
EUR 331.2 |
Description: A rapid test for detection of antibodies (IgG and IgM) for 2019-nCoV, the novel Coronavirus from the Wuhan strain. The test is easy to perform, takes 10 minutes to provide reliable results and is higly specific to the 2019-nCoV Coronavirus. |
2019-nCoV IgG/IgM RapiCard InstaTest for Whole Blood/Serum/Plasma samples |
GEN-176552-50tests |
Cortez Diagnostic |
50 tests |
EUR 566.4 |
Description: A rapid test for detection of antibodies (IgG and IgM) for 2019-nCoV, the novel Coronavirus from the Wuhan strain. The test is easy to perform, takes 10 minutes to provide reliable results and is higly specific to the 2019-nCoV Coronavirus. |
All Sample Diluents Sample Pack |
KF17355 |
Neuromics |
3X100 ml |
EUR 326.4 |
AXYPREP MAG PLASMID KIT- SMALL - 10PREPS- (SAMPLE SIZE) |
MAG-P-10 |
CORNING |
1/pk |
EUR 104.4 |
Description: Bioscience Mag Beads; Magnetic Plasmid |
Plasmid DNA Extraction Mini Kit (Automatic Machine) Sample |
FAPDE-AUTO-024 |
Favorgen |
24 preps |
EUR 31.5 |
Sterile Sample Container for sample coll |
PW016T-1X100NO |
EWC Diagnostics |
1 unit |
EUR 18.77 |
Description: Sterile Sample Container for sample coll |
Sample Treatment Plate |
F402 |
Cygnus Technologies |
1x 96 wells plate |
EUR 123.6 |
|
Description: Sample Treatment Plate by Cygnus Technologies is available in Europe via Gentaur. |
S-adenosylmethionine ELISA kit for plasma, serum, or tissue/cell homogenate samples |
IK00201s |
Arthus |
96 tests |
EUR 699 |
Description: S-adenosylmethionine ELISA kit for plasma, serum, or tissue/cell homogenate samples |
S-adenosylhomocysteine ELISA kit for plasma, serum, or tissue/cell homogenate samples |
IK00301s |
Arthus |
96 tests |
EUR 1349 |
Description: S-adenosylhomocysteine ELISA kit for plasma, serum, or tissue/cell homogenate samples |
Eye Lysate (0 Days Old) |
1420-0 |
ProSci |
0.1 mg |
EUR 229.2 |
Description: Eye tissue lysate (0 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
Lung Lysate (0 Days Old) |
1402-0 |
ProSci |
0.1 mg |
EUR 229.2 |
Description: Lung tissue lysate (0 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
Skin Lysate (0 Days Old) |
1419-0 |
ProSci |
0.1 mg |
EUR 229.2 |
Description: Skin tissue lysate (0 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
Brain Lysate (0 Days Old) |
1403-0 |
ProSci |
0.1 mg |
EUR 229.2 |
Description: Brain tissue lysate (0 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
Liver Lysate (0 Days Old) |
1404-0 |
ProSci |
0.1 mg |
EUR 229.2 |
Description: Liver tissue lysate (0 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
Kidney Lysate (0 Days Old) |
1405-0 |
ProSci |
0.1 mg |
EUR 229.2 |
Description: Kidney tissue lysate (0 Days Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
Stomach Lysate (0 Day Old) |
1415-0 |
ProSci |
0.1 mg |
EUR 229.2 |
Description: Stomach tissue lysate (0 Day Old) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
Sample Diluent |
I094 |
Cygnus Technologies |
1000 ml |
EUR 622.8 |
|
Description: Sample Diluent by Cygnus Technologies is available in Europe via Gentaur. |
Sample Diluent |
I094-100 |
Cygnus Technologies |
100 ml |
EUR 253.2 |
|
Description: Sample Diluent by Cygnus Technologies is available in Europe via Gentaur. |
Sample Diluent |
I094-500 |
Cygnus Technologies |
500 ml |
EUR 447.6 |
|
Description: Sample Diluent by Cygnus Technologies is available in Europe via Gentaur. |
3 Blocking Buffer Sample Pack |
KF17340 |
Neuromics |
3 x 100 ml |
EUR 246 |
S-adenosylmethionine ELISA kit for plasma, serum, or tissue/cell homogenate samples, broad range |
IK00202s |
Arthus |
96 tests |
EUR 749 |
Description: S-adenosylmethionine ELISA kit for plasma, serum, or tissue/cell homogenate samples, broad range |
S-adenosylmethionine ELISA kit for plasma, serum, or tissue/cell homogenate samples, broad range |
IK00203s |
Arthus |
48 tests |
EUR 449 |
Description: S-adenosylmethionine ELISA kit for plasma, serum, or tissue/cell homogenate samples, broad range |
S-adenosylhomocysteine ELISA kit for plasma, serum, or tissue/cell homogenate samples, broad range |
IK00302s |
Arthus |
96 tests |
EUR 1399 |
Description: S-adenosylhomocysteine ELISA kit for plasma, serum, or tissue/cell homogenate samples, broad range |
Sample of P201 |
P201S |
101Bio |
2 rxn |
EUR 69 |
Human IgG-RF stripper/Adsorbent (1 ml, sufficient for stripping 50 samples of 100 ul human serum/plasma) |
RFS-1 |
Alpha Diagnostics |
1 ml |
EUR 123.6 |
Sample Reducing Agent for Protein PAGE 10X |
21440022-1 |
Glycomatrix |
5 mL |
EUR 15.66 |
Sample Reducing Agent for Protein PAGE 10X |
21440022-2 |
Glycomatrix |
10 mL |
EUR 25.75 |
Sample Reducing Agent for Protein PAGE 10X |
21440022-3 |
Glycomatrix |
25 mL |
EUR 42.35 |
BSA Sample Diluent |
F031A |
Cygnus Technologies |
1000 ml |
EUR 585.6 |
|
Description: BSA Sample Diluent by Cygnus Technologies is available in Europe via Gentaur. |
BSA Sample Diluent |
F031A-100 |
Cygnus Technologies |
100 ml |
EUR 234 |
|
Description: BSA Sample Diluent by Cygnus Technologies is available in Europe via Gentaur. |
BSA Sample Diluent |
F031A-500 |
Cygnus Technologies |
500 ml |
EUR 493.2 |
|
Description: BSA Sample Diluent by Cygnus Technologies is available in Europe via Gentaur. |
DNA Sample Diluent |
D006-100 |
Cygnus Technologies |
100 ml |
EUR 447.6 |
|
Description: DNA Sample Diluent by Cygnus Technologies is available in Europe via Gentaur. |
DNA Sample Diluent |
D006-1000 |
Cygnus Technologies |
1000 ml |
EUR 1400.4 |
|
Description: DNA Sample Diluent by Cygnus Technologies is available in Europe via Gentaur. |
DNA Sample Diluent |
D006-500 |
Cygnus Technologies |
500 ml |
EUR 871.2 |
|
Description: DNA Sample Diluent by Cygnus Technologies is available in Europe via Gentaur. |
HEPES Sample Diluent |
I050 |
Cygnus Technologies |
1000 ml |
EUR 632.4 |
|
Description: HEPES Sample Diluent by Cygnus Technologies is available in Europe via Gentaur. |
HEPES Sample Diluent |
I050-100 |
Cygnus Technologies |
100 ml |
EUR 262.8 |
|
Description: HEPES Sample Diluent by Cygnus Technologies is available in Europe via Gentaur. |
HEPES Sample Diluent |
I050-500 |
Cygnus Technologies |
500 ml |
EUR 400.8 |
|
Description: HEPES Sample Diluent by Cygnus Technologies is available in Europe via Gentaur. |
Sample diluent bufer |
AR1106-1 |
Antagene |
30ml |
EUR 150 |
Description: ELISA |
Sample Diluent Buffer |
abx296001-20ml |
Abbexa |
20 ml |
EUR 109.2 |
|
CytoCiteâ„¢ Sample Tube |
CCT100 |
AAT Bioquest |
500 Tubes |
EUR 88 |
Description: Cytocite™ sample tubes are 500 uL thin-walled polypropylene tubes validated for use with Cytocite or Qubit Fluorometer. |
CytoCiteâ„¢ Sample Tube |
CCT100-500Tubes |
AAT Bioquest |
500 Tubes |
EUR 86 |
Description: Cytocite™ sample tubes are 500 uL thin-walled polypropylene tubes validated for use with Cytocite or Qubit Fluorometer. |
Sample Diluent Buffer |
I028-100 |
Cygnus Technologies |
100 ml |
EUR 253.2 |
|
Description: Sample Diluent Buffer by Cygnus Technologies is available in Europe via Gentaur. |
Sample Diluent Buffer |
I028-1000 |
Cygnus Technologies |
1000 ml |
EUR 622.8 |
|
Description: Sample Diluent Buffer by Cygnus Technologies is available in Europe via Gentaur. |
Sample Diluent Buffer |
I028-500 |
Cygnus Technologies |
500 ml |
EUR 447.6 |
|
Description: Sample Diluent Buffer by Cygnus Technologies is available in Europe via Gentaur. |
Zymogram Sample Buffer |
40120378-1 |
Glycomatrix |
25 ml |
EUR 21.7 |
Zymogram Sample Buffer |
40120378-2 |
Glycomatrix |
50 ml |
EUR 35.33 |
Heart Lysate (0 day old mouse) |
1401-0 |
ProSci |
0.1 mg |
EUR 229.2 |
Description: Heart tissue lysate (0 day old mouse) was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT. |
Sample Treatment Buffer |
F175 |
Cygnus Technologies |
1000 ml |
EUR 493.2 |
|
Description: Sample Treatment Buffer by Cygnus Technologies is available in Europe via Gentaur. |
Sample Treatment Buffer |
F175-100 |
Cygnus Technologies |
100 ml |
EUR 262.8 |
|
Description: Sample Treatment Buffer by Cygnus Technologies is available in Europe via Gentaur. |
comb 10 sample, 0.8mm |
EVS3100-C10-0.8 |
Consort |
ea |
EUR 70.8 |
comb 10 sample, 1.5mm |
EVS3100-C10-1.5 |
Consort |
ea |
EUR 70.8 |
comb 12 sample, 0.8mm |
EVS3100-C12-0.8 |
Consort |
ea |
EUR 70.8 |
comb 12 sample, 1.5mm |
EVS3100-C12-1.5 |
Consort |
ea |
EUR 70.8 |
comb 6 sample, 0.8mm |
EVS3100-C6-0.8 |
Consort |
ea |
EUR 70.8 |
comb 6 sample, 1.5mm |
EVS3100-C6-1.5 |
Consort |
ea |
EUR 70.8 |
comb 8 sample, 0.8mm |
EVS3100-C8-0.8 |
Consort |
ea |
EUR 70.8 |
comb 8 sample, 1.5mm |
EVS3100-C8-1.5 |
Consort |
ea |
EUR 70.8 |
Per valutare, in un contesto ambulatoriale, se un punteggio CASI predice accuratamente la gravità / il controllo dell’asma come determinato tramite la valutazione subspecialista. I punteggi del test di controllo dell’asma (ACT) e dei punteggi ACT (C-ACT) dell’infanzia sono stati generati per fornire un contesto aggiuntivo per i punteggi CASI in relazione alle valutazioni utilizzando un altro strumento clinico.